EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

The Complementary Roles of the Prostate Health Index and Multiparametric Magnetic Resonance Imaging in Optimizing the Detection of Clinically Significant Prostate Cancer in Patients With Prostate‐Specific Antigen Levels Below 10 Ng/ mL

Yoshitaka Sekine iD, Gaku Arai iD, Hiroki Kito, Mikio Sugimoto iD, Masaki Shiota iD, Hisashi Hasumi, Kazuto Ito iD, Yoshitomo Kobori iD, Takako Nakada, Takuma Kato iD, Akira Yokomizo iD, Yusuke Ito und 2 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70625 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yoshitaka Sekine und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medicine, Gunma University, Maebashi, Japan. Hauptthemen laut MEDLINE: Multiparametric Magnetic Resonance Imaging, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beckman Coulter Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate complementary roles of Prostate Health Index (phi) and multiparametric magnetic resonance imaging (mpMRI) in detection of any prostate cancer (PC) and clinically significant PC (csPC) and to investigate likelihood of risk stratification for recommending prostate biopsy in men with prostate‐specific antigen (PSA) ≤ 10 ng/mL.

Methods

This exploratory post hoc analysis of the prospective multicenter PROPHET cohort included 108 Japanese men who underwent prebiopsy mpMRI. All MRI findings were retrospectively reviewed by one specialized radiologist and scored using Prostate Imaging Reporting and Data System (PI‐RADS) v2.1. csPC was defined as ISUP grade group (GG) of 2–5. Then, the likelihood of risk stratification for detecting any PC and csPC based on PI‐RADS categories and a significant [−2]proPSA‐related index assessed by receiver operating characteristic (ROC) analyses was retrospectively investigated.

Results

PC was detected in 51 of 108 men (47.2%). The ROC analyses revealed the superiority of phi in detecting PC and csPC. Among men with phi ≤ 36.0 and PI‐RADS 1–3, csPC was detected in 2 of 36 men (5.6%), but no GG 3–5 cancers were observed. In contrast, in men with phi > 36.0, the risk of detecting PC/csPC was 42.9% (9/21)/23.8% (5/21), 42.9% (3/7)/42.9% (3/7), and 89.3% (25/28)/71.4% (20/28) in PI‐RADS 1–2, 3, and 4–5, respectively. Conclusions phi and mpMRI have complementary roles for biopsy decision‐making in men with PSA ≤ 10 ng/mL. Men with phi ≤ 36.0 and PI‐RADS 1–3 may be candidates for biopsy avoidance, whereas phi > 36.0 may be a high‐risk group recommending prostate biopsy regardless of mpMRI findings. Registry and Registration No. of the Study/Trial This study was registered with the UMIN Clinical Trials Registry (UMIN‐CTR), registration number UMIN000047187.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiparametric Magnetic Resonance ImagingProstateProstate-Specific AntigenProstatic NeoplasmsAgedHumansMaleMiddle AgedBiopsyClinical RelevanceImage-Guided BiopsyNeoplasm GradingProspective StudiesRetrospective StudiesRisk AssessmentROC Curve

Stichwörter der Autor:innen

PI‐RADSclinically significant prostate cancermultiparametric magnetic resonance imagingprostate biopsyprostate health index

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medicine, Gunma University, Maebashi, Japan.
  • Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
  • JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan.
  • Department of Urology, Kagawa University Faculty of Medicine, Kagawa, Japan.
  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.

ORCID-Profile: Yoshitaka Sekine, Gaku Arai, Mikio Sugimoto, Masaki Shiota, Kazuto Ito, Yoshitomo Kobori, Takuma Kato, Akira Yokomizo, Kazuhiro Suzuki

Förderung

  • Beckman Coulter Inc.

Zitieren

APA

Sekine, Y., Arai, G., Kito, H., Sugimoto, M., Shiota, M., Hasumi, H., Ito, K., Kobori, Y., Nakada, T., Kato, T., Yokomizo, A., Ito, Y., Suzuki, K., & Kaji, Y. (2026). The Complementary Roles of the Prostate Health Index and Multiparametric Magnetic Resonance Imaging in Optimizing the Detection of Clinically Significant Prostate Cancer in Patients With Prostate‐Specific Antigen Levels Below 10 Ng/ mL. International Journal of Urology. https://doi.org/10.1111/iju.70625

Vancouver

Sekine Y, Arai G, Kito H, Sugimoto M, Shiota M, Hasumi H, et al. The Complementary Roles of the Prostate Health Index and Multiparametric Magnetic Resonance Imaging in Optimizing the Detection of Clinically Significant Prostate Cancer in Patients With Prostate‐Specific Antigen Levels Below 10 Ng/ mL. International Journal of Urology. 2026. doi:10.1111/iju.70625

BibTeX
@article{Sekine2026,
  author = {Sekine, Yoshitaka and Arai, Gaku and Kito, Hiroki and Sugimoto, Mikio and Shiota, Masaki and Hasumi, Hisashi and Ito, Kazuto and Kobori, Yoshitomo and Nakada, Takako and Kato, Takuma and Yokomizo, Akira and Ito, Yusuke and Suzuki, Kazuhiro and Kaji, Yasushi},
  title = {The Complementary Roles of the Prostate Health Index and Multiparametric Magnetic Resonance Imaging in Optimizing the Detection of Clinically Significant Prostate Cancer in Patients With Prostate‐Specific Antigen Levels Below 10 Ng/ mL},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70625}
}
Kostenlos starten →